Value of 18F-FAPI PET/CT in evaluating early-stage of liver graft fibrosis in adult liver transplanta-tion recipients
Objective To explore the value of 18F-fibroblast activation protein inhibitor(FAPI)PET/CT in the assessment of early-stage graft fibrosis(S1-S2)after liver transplantation(LT).Methods From November 2021 to April 2022,17 adult liver transplant recipients(12 males and 5 females;age(52.6±7.9)years)in the Affiliated Hospital of Qingdao University were enrolled retrospectively in this study.All 17 patients received laboratory examinations,FibroScan,18F-FAPI PET/CT and liver biopsy.According to the Scheuer scoring system,hepatic tissue was divided into no fibrosis(SO)and early fibrosis(S1-S2).Independent-sample t test was used to compare SUVmax between two groups,and Mann-Whitney U test was used to compare liver stiffness measurement(LSM).ROC curve analysis was used to evaluate the diagnostic efficacy of LSM and SUVmax in the early fibrosis of liver grafts.Delong test was used to compare the differ-ence of AUCs.Results Among 17 adult LT recipients,11 were in stage SO,5 were in stage S1,and 1 was in stage S2.There were significant differences in LSM and SUVmax between no fibrosis group and early fibro-sis group(LSM:5.4(4.7,6.6)vs 12.9(5.6,19.9)kPa,z=-2.01,P=0.044;SUVmax:1.7±0.8 vs 3.9±1.6,t=-3.14,P=0.019).The threshold value of LSM in predicting early-stage graft fibrosis was 8.2 kPa and the AUC was 0.80(95％CI:0.54-0.95),which was 2.0 and 0.92(95％CI:0.78-1.00)for SUVmax respectively.There was no significant difference in AUC between the two tools(z=0.80,P=0.421).Con-clusion 18F-FAPI PET/CT can precisely evaluate the early fibrosis of allografts,with the similar diagnostic efficacy with FibroScan(LSM),which is expected to be a new non-invasive diagnostic tool for predicting the early-stage of graft liver fibrosis.
Liver transplantationFibrosisFibroblastsAntagonists and inhibitorsPositron-emission tomographyTomography,X-ray computed
NETL
NSTL
万方数据
